Key facts
- PorMedTec’s last known valuation is $23.0M (Jan 2025).
- It has raised $5.4M; the latest was Later Stage VC ($3.3M) in Jan 2025.
- Notable investors include Global Brain, Eight Roads, IDDM Network, JGC Holdings.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for PorMedTec
- ·The full record, as it builds
Funding rounds
No funding rounds for PorMedTec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PorMedTec
Developer of genetic engineering and somatic cell cloning technology intended for xenotransplantation with core strengths in pig cloning and related reproductive technologies. The company develops and produces pigs as evaluation targets for drug efficacy pharmacology tests or performance tests of medical devices and for the business that aims to fulfill unmet medical needs, including the shortage of organ donations, enabling medical experts to solve all issues using personalized and regenerative medicine.
- Sector
- Healthcare
- HQ
- Kawasaki, Japan
- Founded
- 2017
- Employees
- 10
- Website
- pormedtec.com/
- Ownership
- Privately Held (backing)
PorMedTec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PorMedTec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PorMedTec in its N-PORT filings yet. We sweep new filings monthly.